Multiple Myeloma
Feature
From Beirut to frontline hematology research
A young Lebanese-American physician scientist keeps ‘smoldering’ myeloma in his sights and a sick relative in mind.
From the Journals
AFib risk with cancer drugs underestimated
Many cancer therapies increase the risk of atrial fibrillation, but this is underreported in clinical trials.
From the Journals
Erythema extent predicts death in cutaneous GVHD
Study: Extent of skin erythema correlates with deaths from graft-versus-host disease in blood cancer patients after stem cell transplants.
From the Journals
Maintenance therapies boost MM survival rates
Interim results in the phase 3 ATLAS trial seemed to buttress the benefits of intensive maintenance therapies for multiple myeloma, post...
News
FDA calls for withdrawal of multiple myeloma drug Pepaxto
A confirmatory trial to show clinical benefit raised concerns about safety.
Sponsored Supplement
Activating the Immune System to Treat Multiple Myeloma
Feature
Multiple myeloma diagnosed more via emergency care during COVID
While trying to avoid COVID-19 infection, patients ultimately diagnosed with multiple myeloma may have delayed interactions with healthcare...
Conference Coverage
‘Exciting’ responsiveness to talquetamab for r/r MM
The novel antibody talquetamab may buy time for patients with multiple myeloma (MM) for whom few other options remain.
News
Blenrep for multiple myeloma withdrawn from U.S. market
As requested by the U.S. Food and Drug Administration, the multiple myeloma drug blenrep is being taken off the market after disappointing results...
Feature
Teclistamab for MM: Lifesaver or 'cause of death'?
In the wake of the FDA’s accelerated approval of teclistamab, myeloma specialists interpret the pros and cons.
News
FDA OKs teclistamab for relapsed/refractory multiple myeloma
FDA has approved teclistamab as a new treatment option for heavily pretreated adults with relapsed/refractory multiple myeloma.
From the Journals
CAR T-cell therapy neurotoxicity linked to NfL elevations
Even prior to CAR T-cell therapy, patients developing related neurotoxic complications show elevated markers of neuronal injury.